Participants criticize the NYT article as alarmist and pharma-influenced, arguing that high costs and insurance denials drive demand for alternatives. They note differences between grey and black markets, question patent extensions that keep prices elevated, and point to conflicts of interest in coverage. Some expect little price relief until patents fully lapse, while others see insurance reform as a possible future factor.
What this discussion establishesWhether insurers are justified in limiting coverage given the number of potential patients and long exclusivity periods
Still openHow soon or whether these medications will become substantially more affordable through generics or policy changes
Nothing here is advice.
These sensational reports never sit well with me in the slightest.
It's amusing how these pieces toss out just a quick nod toward the real question of why folks opt for unofficial routes over major drug firms. They skip right past concerns like getting hold of things or their expense, and go straight to hyping up the dangerous criminal scene instead.
Comments highlight an angle the piece skips over entirely. Coverage rules often push folks away from these helpful treatments or block any chance to start them. That pressure leaves plenty feeling stuck and willing to explore unofficial routes instead. Plenty more lack coverage in the first place. The person featured clearly weighed hundreds of pounds yet received too little support from his care team or plan. How does anyone in that spot handle things? Watching food amounts and staying active just fails for those carrying extreme extra weight.
That earlier statement misses the mark entirely. Health coverage providers have good reason for rejecting payments to major drug producers at such levels. Because the vast majority of grown-ups here struggle with excess weight, combined with an extended exclusive marketing window, those companies stand to gain huge sums that would more than recoup their research and regulatory costs multiple times over, even at lower rates. Moreover, the payers would end up authorizing treatment for just about anybody without much trouble.
It's annoying how much work goes into twisting the facts with slippery phrasing and one-sided wording. It kicks off in the headline with talk of an underground trade, even though grey and black channels aren't the same thing at all. Anyone who's brought in specialty vehicles from overseas could spell out the split. The piece acts like no outside lab checks are possible to confirm the contents. The reporter works hard to paint the whole thing as frightening. The story also hands the manufacturer space to talk, and that statement stands out as extreme. The compound itself has a documented structure. Just one version of it exists. It can be made in a lab, checked for purity, and quantified exactly. It's like a beverage firm insisting their water formula can't be matched by anyone else. Naturally the writer offers zero pushback, so the company wraps up that part without interruption. Some regulatory opening. Consider what happens if the same logic gets used on other risky goods, like a gadget maker stamping their items with a note that they're not meant for violent misuse, which might let them dodge certain product rules. You can picture how patching that opening would require reading motives into actions where none were declared. This amounts to projecting your own assumptions. Moving ahead, the text grows repetitive. Whole sections lay out why official clearance carries weight and what follows from breaking those standards. Fear gets applied by spelling out enforcement moves in lengthy terms. The same approach shows up when harm numbers come up, yet even if the total checks out, the substance appears to have helped far more people than it damaged, leaving a positive overall balance. They skip any mention of actual fatalities or any breakdown of cases, since they understand what surfaces once those claims get examined. At bottom the writer and the outlet push a corporate line. This reporter has mostly covered fluff in earlier pieces. The paper is led by someone whose family member sits on the drug firm's board and has held seats at card networks and food retailers as well. These aren't straightforward actors, and I'm worn out from constant spin.
I fully back what you shared and hope you keep saying it.
Haven't you gone over my remark yet? 🙄
That rings true. Might those glp1s cost less down the road?
Doubtful it'll happen prior to the patents ending and generics being available.
This person holds a seat among the directors at that major drug company. Doesn't that point to some serious bias here?
I figure companies will lock in rights to some alternative way of getting the existing versions into people then announce they've found risks with prior approaches leading to limits or outright blocks. On top of that fresh options they're working on will push the current medications into seeming outdated even though plenty of users still get good results from them. These days even the unofficial channels have those compounds mostly unavailable now.
One medication triggered harsh stomach troubles for me yet the other produced only light discomfort overall. Plenty of folks seem to have noticed the same pattern themselves.
Propaganda article, bought and paid for by the company.
I've noticed folks view insurers more positively than they have in ages. Despite their influence efforts, I figure policy shifts in this area could emerge as a key campaign topic before long, and the support gained by backing those shifts might drive meaningful adjustments in the field, not enormous ones but noticeable, though it'll unfold slowly. Drug makers will likely push for it too, since right now the biggest obstacle to them raking in far higher profits is coverage refusals for these medications. From talks I've caught, their top people see the chance clearly and are probably directing funds toward politicians to move things forward, given how strong the potential gains look.
Even after protection on these treatments ends, laws still favor the initial generic producer and keep competitors out. Consider what happened with one medication that lost protection this year overseas. Producers there had prepared in advance and several generics hit the market immediately upon expiration. Monthly costs there seem quite affordable. The maker attempted additional patents and legal challenges against generics, but these didn't hold up under local regulations. For a related but weaker treatment that lost protection years earlier in our market, the same tactics succeeded and delayed generics until recently. Even now, years after, the generic version remains expensive monthly. The version aimed at weight reduction likely has further extensions. I wouldn't anticipate affordable generic versions of this class of treatments becoming available at sensible prices.
If you have tried it, this topic is still open. Sign in to reply — it takes a minute.